In 2004, ACQUITY UPLC® gave future-focused labs the highest level of chromatographic performance the world had ever seen. Then came a dramatically greater demand for better results in less time. And UPLC® quickly went from leading-edge luxury to global necessity
LEGENDARY ACQUITY PERFORMANCE.AT EVERY LEVEL FOR EVERY LAB.
In 2004, ACQUITY UPLC® gave future-focused labs the highest level of chromatographic performance the world had ever seen. Then came a dramatically greater demand for better results in less time. And UPLC® quickly went from leading-edge luxury to global necessity.
Today, Waters meets the ever-growing demand for higher levels of resolution and sensitivity with an ever-growing family of ACQUITY® Systems. That means for virtually any application, in every analytical lab, all over the world, there’s an ACQUITY System that’s right for you. To find the one that’s right for your lab, visit waters.com/ACQUITY.
Corporate Headquarters
Waters Corporation
34 Maple Street
Milford, MA 01757
T: 508-478-2000 or 1-800-252-4752
F: 508-872-1990
European Headquarters
Waters S.A.S.
BP 608
78056 Saint-Quentin
En Yvelines Cedex, France
T: 33 1 30 48 72 00
F: 33 1 30 48 72 01
www.waters.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.